Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|May 17, 2024

Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

Author(s)Stephanie L. Graff, MD

Stephanie Graff, MD, concludes the discussion with thoughts on endocrine therapies in development for patients with ER+/HER2- metastatic breast cancer.

Episodes in this series

EP. 1 Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP. 1 Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP. 2 Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP. 2 Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP. 3 Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP. 3 Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP. 4 ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP. 4 ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP. 5 Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP. 5 Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP. 6 Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP. 6 Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP. 7 Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP. 7 Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP. 8 Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

EP. 8 Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 9 Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 10 Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer

Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"

EP. 11 The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"

EP. 12 Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD, an expert on breast cancer

EP. 13 Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Rani Bansal, MD | Image Credit: Duke Department of Medicine

Closing the Gaps: Breast Cancer Clinical Trials, Minority Representation, and What Young Patients Need to Hear with Rani Bansal, MD

ByElla Hohmann, MS,Rani Bansal, MD

June 1st 2026

Rani Bansal, MD | Image Credit: Duke Department of Medicine

Rani Bansal, MD: Breast Cancer in Young Women: Subtypes, Risk Factors, and Self-Advocacy

ByElla Hohmann, MS,Rani Bansal, MD

May 26th 2026

Jessica Paulus, ScD | Image: LinkedIn

Does Physician Education on New NCCN Guidelines Change Behavior? Data From Ontada Say, “Yes”

May 25th 2026

Datroway becomes the first TROP2-directed ADC approved for first-line metastatic triple-negative breast cancer. | Image Credit: Pawel - stock.adobe.com

Datopotamab Deruxtecan Wins First-Line FDA Approval for Immunotherapy-Ineligible Triple-Negative Breast Cancer

ByElla Hohmann, MS

May 22nd 2026

Rani Bansal, MD, breaks down why breast cancer is rising in women under 50 and why risk-based screening may be the key.

Rani Bansal, MD: What's Driving Rising Cancer Rates in Young Women and Are We Screening Early Enough?

ByElla Hohmann, MS,Rani Bansal, MD

May 20th 2026

Trending on AJMC

FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301

New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease

Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship

Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home

Odronextamab Plus CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Matthew Matasar, MD